QIAGEN N.V. (Nasdaq: QGEN) is the leading provider of molecular diagnostics products and the world's premier supplier of solutions for preanalytical sample preparation.
Pathway Diagnostics Corporation (Malibu, CA) is pharmaceutical industry’s pioneer in biomarker development and testing services.
The two companies entered into a new co-marketing partnership that allows customers in the biotechnology and pharmaceutical industries to leverage QIAGEN's sample and assay technology platforms in combination with Pathway Diagnostics' clinical development and testing service capabilities.
Find more details from the press release.The pharmaceutical industry is currently accelerating its focus on the co-development and co-validation of biomarker assays with therapeutics.
These biomarker assays are intended to improve drug development efficiency by improving patient selection and clinical trial outcomes, accelerating time-to-market cycles for new drugs, and reducing clinical trial costs.
In some cases, biomarker development may lead to companion diagnostic products that will be utilized as a prerequisite for therapeutic intervention.
Comment Preview